# A Feasibility Study of Ketorolac Treatment for Cachexia in Patients With Advanced Pancreatic Ductal Adenocarcinoma

> **NCT05336266** · EARLY_PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Andrew Hendifar, MD** · enrollment: 28 (actual)

## Conditions studied

- Pancreas Cancer
- Pancreatic Ductal Adenocarcinoma
- Pancreatic Cancer

## Interventions

- **DRUG:** Ketorolac Tromethamine

## Key facts

- **NCT ID:** NCT05336266
- **Lead sponsor:** Andrew Hendifar, MD
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-07-01
- **Primary completion:** 2025-02-19
- **Final completion:** 2026-12-05
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2026-01-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05336266

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05336266, "A Feasibility Study of Ketorolac Treatment for Cachexia in Patients With Advanced Pancreatic Ductal Adenocarcinoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05336266. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*